Myos Rens Technology (Myos Rens Technology) Cash-to-Debt : 0.70 (As of Sep. 2020)

View and export this data going back to 2010. Start your Free Trial

What is Myos Rens Technology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Myos Rens Technology's cash to debt ratio for the quarter that ended in Sep. 2020 was 0.70.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Myos Rens Technology couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2020.

The historical rank and industry rank for Myos Rens Technology's Cash-to-Debt or its related term are showing as below:

MYOS's Cash-to-Debt is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.945
* Ranked among companies with meaningful Cash-to-Debt only.

Myos Rens Technology Cash-to-Debt Historical Data

The historical data trend for Myos Rens Technology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Myos Rens Technology Cash-to-Debt Chart

Myos Rens Technology Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Cash-to-Debt

Get a 7-Day Free Trial

1.30

No Debt

0.02

0.05

Myos Rens Technology Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Cash-to-Debt	Get a 7-Day Free Trial															0.40	0.05	0.82	1.18	0.70

Competitive Comparison of Myos Rens Technology's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Myos Rens Technology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myos Rens Technology's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Myos Rens Technology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Myos Rens Technology's Cash-to-Debt falls into.

Myos Rens Technology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Myos Rens Technology's Cash to Debt Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.064	/	(1.205	+	0.146)
	=	0.05

Myos Rens Technology's Cash to Debt Ratio for the quarter that ended in Sep. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.791	/	(0.723	+	0.405)
	=	0.70

Myos Rens Technology (NAS:MYOS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Myos Rens Technology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Myos Rens Technology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Myos Rens Technology (Myos Rens Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Myos Rens Technology Inc (NAS:MYOS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

45 Horsehill Road, Suite 106, Cedar Knolls, NJ, USA, 07927

Website

https://www.myosrens.com

Myos Rens Technology Inc is a US-based bio-nutrition and biotherapeutics company. It focuses on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. The company develops nutritional and therapeutic products for maintaining and improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases such as Sarcopenia, Cachexia, and others.

Executives

Joseph Mannello	director, officer: Chief Executive Officer	C/O BREAN CAPITAL, LLC, 1345 AVENUE OF THE AMERICAS, 29TH FLOOR, NEW YORK NY 10105
Victor E Mandel	director	PO BOX 5962, WASHINGTON DC 20016
Robert J Hariri	director	341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Christopher Pechock	director	C/O MATLINPATTERSON GLOBAL ADVISORS INC, 520 MADISON AVE, NEW YORK NY 10022-4213
Christopher C Dewey	director	120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Louis J. Aronne	director	4640 ADMIRALTY, SUITE 500, MARINA DEL RAY CA 90292
Eric Zaltas	director	45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ 07927
Andrew Joel Ponte	director	45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
David J Matlin	10 percent owner
John Nosta	director	45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Zhengguang Lyu	director	16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Ren Ren	director, 10 percent owner	16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Rens Technology Inc	10 percent owner	150 DRAKE STREET ROOM 7F, POMONA CA 91767
Rens Agriculture Science & Technology Co, Ltd	10 percent owner	16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Guiying Zhao	director	16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019